コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 able inflammatory responses to cause primary pneumonic plague.
2 to become the causative agent of bubonic and pneumonic plague.
3 fferentiation primary response 88 (MyD88) in pneumonic plague.
4 sease that can manifest as either bubonic or pneumonic plague.
5 and F1 antigens protected mice in a model of pneumonic plague.
6 ce for the pathogenesis of plague, including pneumonic plague.
7 e cells to vaccine-primed protection against pneumonic plague.
8 . pestis infection, an experimental model of pneumonic plague.
9 terized an intranasal mouse model of primary pneumonic plague.
10 llular immunity will most effectively combat pneumonic plague.
11 ion, protected mice in models of bubonic and pneumonic plague.
12 stis KIM, the etiologic agent of bubonic and pneumonic plague.
13 of Yersinia pestis, the agent of bubonic and pneumonic plague.
14 bacterium Yersinia pestis results in primary pneumonic plague.
15 ormation and expansion or protection against pneumonic plague.
16 m that is the causative agent of bubonic and pneumonic plague.
17 CO92 in mouse and rat models of bubonic and pneumonic plague.
18 . pestis CO92 in mouse models of bubonic and pneumonic plague.
19 dent manner in the lungs during experimental pneumonic plague.
20 able impact on the progression or outcome of pneumonic plague.
21 pestis causes the fatal respiratory disease pneumonic plague.
22 nuation at 11 or 12 LD50 in a mouse model of pneumonic plague.
23 3SS as a potential vaccine candidate against pneumonic plague.
24 icantly protected from developing subsequent pneumonic plague.
25 pha and IFN-gamma in protecting mice against pneumonic plague.
26 d for production of bubonic, septicemic, and pneumonic plague.
27 a pestis, the causative agent of bubonic and pneumonic plague.
28 mportant for development of both bubonic and pneumonic plague.
29 ing specific roles for these pathways during pneumonic plague.
30 d lethality in murine models of systemic and pneumonic plague.
31 ironment during the preinflammatory phase of pneumonic plague.
32 , Yersinia-specific sRNA in a mouse model of pneumonic plague.
33 positive strains of Y. pestis in bubonic and pneumonic plague.
34 th Yersinia pestis, the agent of bubonic and pneumonic plague.
35 a live attenuated cell-based vaccine against pneumonic plague.
36 bt, that plays a role in the pathogenesis of pneumonic plague.
37 anism and the causative agent of bubonic and pneumonic plague.
38 for virulence in mouse models of bubonic and pneumonic plague.
39 the use of an iron dextran-treated model of pneumonic plague.
40 pigmented Yersinia pestis does not result in pneumonic plague.
41 e was no disease pathology characteristic of pneumonic plague.
42 tis primes T cells that protect mice against pneumonic plague.
43 n in virulence in mouse models of bubonic or pneumonic plague.
44 derivative, V10, to protect these rats from pneumonic plague.
45 pestis is the etiologic agent of bubonic and pneumonic plagues.
46 ulmonary infection by Yersinia pestis causes pneumonic plague, a necrotic bronchopneumonia that is ra
49 ulmonary infection by Yersinia pestis causes pneumonic plague, a rapidly progressing and often fatal
51 pestis is the causative agent of bubonic and pneumonic plague, an acute and often fatal disease in hu
52 am-negative bacterium Yersinia pestis causes pneumonic plague, an acutely lethal septic pneumonia.
53 he potential virulence properties of Psa for pneumonic plague, an Escherichia coli strain expressing
55 on with the bacterium Yersinia pestis causes pneumonic plague, an often-fatal disease for which no va
56 rat as an alternative small animal model for pneumonic plague and characterized both the efficacy and
57 studying T-cell-mediated protection against pneumonic plague and demonstrates the capacity for live,
58 early host/pathogen interactions that define pneumonic plague and showcase the utility of human preci
59 ling early host/pathogen interactions during pneumonic plague and solidify the role of Pla in promoti
60 ficantly affected by the Pla protease during pneumonic plague, and although A2AP participates in immu
61 ynergistically in protecting animals against pneumonic plague, and we have demonstrated an immunologi
62 onsequences of neutrophil recruitment during pneumonic plague, and we studied the susceptibility of C
63 rsinia pestis-laden aerosols that results in pneumonic plague, arming both the mucosal and systemic i
64 s protective immunity to prevent bubonic and pneumonic plague, as well as yersiniosis, in mice and wo
65 n CO92 and screened them in a mouse model of pneumonic plague at a dose equivalent to 5 50% lethal do
66 dicate that Y. pestis was capable of causing pneumonic plague before it evolved to optimally cause in
67 lly virulent in animal models of bubonic and pneumonic plague but also break through immune responses
68 is essential for Y. pestis to cause primary pneumonic plague but is less important for dissemination
69 d Yersinia pestis confers protection against pneumonic plague but is not considered safe for general
71 ation protected mice from lethal bubonic and pneumonic plague caused by CO92, a wild-type F1+ strain,
76 ation resulted in partial protection against pneumonic plague challenge with 250 MLD Y. pestis CO92,
77 responses and protection against bubonic and pneumonic plague challenges, with 80% and 90% survival,
78 o longer responsible for pandemic outbreaks, pneumonic plague continues to be a challenge for medical
79 side-ciprofloxacin group died, and secondary pneumonic plague developed in 3 patients in each group.
80 ague have highlighted a significant role for pneumonic plague during outbreaks of Y. pestis infection
81 is review we describe the characteristics of pneumonic plague, focusing on its disease progression an
82 Yersinia pestis, which causes bubonic and pneumonic plague, forms pigmented red colonies on Congo
83 lence testing in mouse models of bubonic and pneumonic plague found only a modest increase in surviva
84 a pestis, the causative agent of bubonic and pneumonic plagues, has undergone detailed study at the m
85 course, severity, and difficulty of treating pneumonic plague highlight how differences in the route
86 protease is essential for the development of pneumonic plague; however, the complete repertoire of su
88 severely attenuated Y. pestis CO92 to evoke pneumonic plague in a mouse model while retaining the re
93 ented Y. pestis were reported to cause fatal pneumonic plague in mice, suggesting a useful model for
97 ting type III secretion in the prevention of pneumonic plague in rats and reveal critical contributio
98 deeply rooted strains of Y. pestis to cause pneumonic plague, indicating that Y. pestis was primed t
109 m-negative bacterium that causes bubonic and pneumonic plague, is able to rapidly disseminate to othe
113 double mutant was still fully virulent in a pneumonic plague model but had an approximately 90-fold
114 he Deltalpp or DeltamsbB single mutant, in a pneumonic plague model were significantly protected agai
115 Surprisingly, via intranasal instillation (pneumonic plague model), we saw a difference in the viru
121 caf mutant was as virulent as WT CO92 in the pneumonic plague mouse model; however, it was attenuated
122 mized, controlled efficacy trials in the AGM pneumonic plague nonhuman primate model together with th
124 t failure defined as death, fever, secondary pneumonic plague, or alternative or prolonged plague tre
129 We hypothesized that the pathophysiology of pneumonic plague resulting from expression of proteins e
131 that protect mice against bubonic plague and pneumonic plague, suggesting that rV10 may serve as an i
133 ulence factors required for the induction of pneumonic plague that are independent of iron scavenging
134 ared to the WT bacterium in a mouse model of pneumonic plague, the Deltalpp Deltaail double mutant an
136 le this modification is unnecessary to cause pneumonic plague, the substitution is instead needed to
137 can green monkey (AGM) inhalational model of pneumonic plague to test the efficacy of gepotidacin.
138 utant and comparing its ability in mediating pneumonic plague to that of the wild type in two animal
140 ary Y. pestis challenge, and we suggest that pneumonic plague vaccines should aim to induce mixed typ
141 vations strongly suggest that development of pneumonic plague vaccines should strive to prime both CD
142 To aid the development of safe and effective pneumonic plague vaccines, we are deciphering mechanisms
143 y host response during the course of primary pneumonic plague was investigated in two mouse strains,
145 tis virulence in mouse models of bubonic and pneumonic plague, we characterized an msbB in-frame dele
146 sing the C57BL/6 mouse models of bubonic and pneumonic plague, we determined that all of these genes
147 produces a severe primary pneumonia known as pneumonic plague, which is contagious and highly lethal
148 esidues 271-300, elicited protection against pneumonic plague, which seemed to be based on conformati